+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
5-Alpha Reductase Deficiency Market by Treatment Type, Formulation, Route Of Administration, Distribution Channel, End User, Age Group - Global Forecast to 2030- Product Image
5-Alpha Reductase Deficiency Market by Treatment Type, Formulation, Route Of Administration, Distribution Channel, End User, Age Group - Global Forecast to 2030- Product Image
Sale

5-Alpha Reductase Deficiency Market by Treatment Type, Formulation, Route Of Administration, Distribution Channel, End User, Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014980
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The 5-Alpha Reductase Deficiency Market grew from USD 1.28 billion in 2024 to USD 1.41 billion in 2025. It is expected to continue growing at a CAGR of 9.92%, reaching USD 2.26 billion by 2030.

Unveiling the Therapeutic Frontier of 5-Alpha Reductase Deficiency

The 5-Alpha Reductase Deficiency market revolves around a rare genetic condition that impedes the conversion of testosterone into dihydrotestosterone, manifesting in diverse clinical challenges ranging from undervirilization to hair loss. In recent years, stakeholders have intensified their focus on pharmacological interventions, particularly with inhibitors such as Dutasteride and Finasteride. Emerging evidence underscores the importance of early diagnosis and personalized therapy, propelling innovation across treatments and formulations.

This Executive Summary synthesizes critical developments, regulatory dynamics, and market drivers shaping the therapeutic landscape. It offers an integrative perspective designed to inform drug developers, healthcare providers, payers, and investors about the latest clinical insights, competitive positioning, and strategic avenues for growth. By highlighting transformative shifts, tariff impacts, segmentation intelligence, regional variations, and actionable recommendations, this report provides a foundational blueprint for navigating the complexities of this niche yet rapidly evolving market.

Evolving Care Paradigms Redefine Treatment Standards

Recent years have witnessed transformative shifts in the landscape of 5-Alpha Reductase Deficiency management, driven by scientific breakthroughs and evolving patient demands. Advances in genomic profiling and biomarker discovery have refined diagnostic accuracy, enabling clinicians to tailor therapy based on subtype and severity. Concurrently, novel formulations and delivery mechanisms have emerged, with extended-release capsules and topical solutions offering improved tolerability and patient adherence.

Simultaneously, digital health integration-from telemedicine consultations to mobile adherence platforms-has redefined patient engagement, facilitating remote monitoring and real-time feedback loops. The convergence of precision medicine and digital tools is fostering a more holistic care paradigm, empowering patients and providers to collaborate on long-term outcome optimization. This shift underscores the industry’s transition from one-size-fits-all approaches to individualized regimens that address both physiological and psychosocial dimensions of the disorder.

Navigating Tariff-Induced Transformations in 2025 Supply Chains

The introduction of revised United States tariffs in 2025 has introduced new dynamics in the importation of active pharmaceutical ingredients and finished dosage forms used in 5-Alpha Reductase Deficiency therapies. Manufacturers sourcing raw materials from international suppliers have encountered increased cost pressures, prompting a reassessment of supply chain strategies. In response, several industry leaders have initiated onshore manufacturing expansions to mitigate tariff exposure and ensure continuity of supply.

At the same time, downward pricing pressure on imported generics has intensified competition, compelling innovators to fortify intellectual property defenses and explore differentiated formulations that can command premium pricing. Despite these headwinds, the domestic manufacturing uptick has spurred job creation and investments in advanced production capabilities, positioning the United States as a more self-reliant hub for critical compounds. Looking forward, strategic alliances between API producers and formulation specialists are expected to further stabilize supply chains and safeguard against future tariff fluctuations.

Decoding Market Segments to Uncover Growth Avenues

A nuanced breakdown across treatment type, formulation, route of administration, distribution channel, end user, and age group reveals distinct pockets of growth and unmet needs. The divide between Dutasteride and Finasteride therapies highlights varying potency profiles and safety considerations, driving prescriber preferences based on patient-specific risk assessments. Meanwhile, the proliferation of formulation variants-capsules available in both extended and immediate release, concentrated and standard solutions, and tablets with tailored release kinetics-addresses a spectrum of pharmacokinetic requirements and enhances patient customization.

Oral administration remains the primary route, though topical options are gaining traction among patients prioritizing localized action and minimized systemic exposure. Distribution channels encompass hospital pharmacies-both private and public-online portals under manufacturer branding or through third-party marketplaces, as well as chain and independent retail pharmacies. At the point of care, dermatology and urology clinics are pivotal settings, complemented by home care models that range from caregiver administration to self-managed regimens, and by general and specialty hospitals. Across all segments, adult patients represent the core demographic, with geriatric and pediatric subgroups warranting specialized dosing strategies and safety monitoring.

Regional Dynamics Shaping Access and Adoption Patterns

Geographical dynamics exert a profound influence on market trajectories, with each region exhibiting unique drivers and barriers. In the Americas, strong regulatory frameworks and a well-established generic market drive robust competition, while high healthcare spending facilitates rapid adoption of innovative therapies. Public and private insurers play a pivotal role in reimbursement policies, shaping access pathways and influencing formulary inclusion.

By contrast, Europe, Middle East & Africa present a heterogeneous landscape characterized by varied pricing controls, divergent regulatory standards, and differential uptake of branded agents. Centralized procurement mechanisms coexist with country-specific tender systems, necessitating adaptive market entry strategies. Emerging markets within the region offer growth potential, though infrastructural constraints and affordability challenges underscore the need for tiered pricing models.

Asia-Pacific embodies a dual narrative: mature markets such as Japan and Australia showcase strong demand for novel formulations and value-added services, whereas emerging economies emphasize cost-containment and generic substitution. Local manufacturing partnerships and regional clinical studies are increasingly integral to market access, reflecting a shift toward collaborative models that bridge global expertise with local insights.

Competitive Landscape Driven by Innovation and Collaboration

The competitive arena is defined by a blend of established pharmaceutical giants, niche specialty firms, and emerging biotechs advancing differentiated therapies. Market incumbents leverage extensive distribution networks and robust R&D pipelines to maintain leadership in both branded and generic segments. In parallel, specialist companies concentrate on innovative delivery platforms-such as nanoparticle-based topicals-and on combination regimens that address ancillary symptoms like scalp inflammation and dermal irritation.

Strategic collaborations between formulation experts and contract manufacturing organizations have accelerated time-to-market for novel dosage forms, while licensing agreements enable smaller firms to expand geographic reach. Additionally, several players are investing in real-world evidence studies and patient registries to demonstrate long-term safety and efficacy, thereby strengthening market positioning and supporting premium pricing. This multifaceted competitive landscape underscores the importance of agility, strategic partnerships, and evidence-based differentiation.

Strategic Imperatives for Sustained Market Leadership

Industry leaders can capitalize on emerging opportunities by prioritizing precision-guided therapies and patient-centric service models. Investing in next-generation formulations that enable flexible dosing and improved bioavailability will address key adherence challenges. Leveraging digital platforms for remote monitoring, educational support, and adherence reminders can enhance patient engagement and generate valuable real-world data.

Expanding local manufacturing capabilities and forging supply chain alliances will mitigate tariff risks and bolster resilience. Stakeholders should also explore value-based contracting arrangements with payers, aligning reimbursement to clinical outcomes and reinforcing the economic argument for innovative treatments. Finally, cultivating partnerships with patient advocacy groups and clinical research networks will facilitate faster trial enrollment, enrich evidence generation, and amplify market access efforts across diverse regions.

Robust Methodology Underpinning Actionable Insights

This report synthesizes insights derived from a multi-phased research methodology encompassing primary interviews, secondary data triangulation, and rigorous qualitative and quantitative analyses. Detailed discussions with key opinion leaders, endocrinologists, dermatologists, and urologists provided firsthand perspectives on clinical practice trends and unmet patient needs. Complementing these interviews, a comprehensive review of regulatory filings, clinical trial registries, and peer-reviewed publications ensured a robust evidence base.

Market segmentation and regional dynamics were validated through in-depth consultations with distribution channel experts, reimbursement analysts, and procurement authorities. Competitive benchmarking leveraged company financial reports, patent databases, and strategic partnership disclosures. Finally, editorial oversight and expert panel reviews ensured the accuracy, relevance, and clarity of all findings, delivering a cohesive narrative that supports informed decision-making.

Synthesizing Market Drivers to Chart Future Growth

The landscape of 5-Alpha Reductase Deficiency treatment is at an inflection point, shaped by scientific innovation, regulatory evolution, and shifting market forces. As tariffs reshape supply chains and emerging technologies redefine care delivery, stakeholders must adopt agile strategies that balance cost-efficiency with clinical differentiation. Segmentation analysis and regional intelligence highlight targeted growth pockets, while competitive insights underscore the imperative for collaboration and evidence-driven positioning.

Ultimately, the most resilient players will be those who anticipate patient and payer priorities, invest in flexible manufacturing and distribution models, and harness data-driven approaches to demonstrate value. By embracing these principles, companies can navigate the complexities of the market, drive meaningful patient outcomes, and secure sustainable growth in this specialized therapeutic arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Dutasteride
    • Finasteride
  • Formulation
    • Capsule
      • Extended Release
      • Immediate Release
    • Solution
      • Concentrated
      • Standard
    • Tablet
      • Extended Release
      • Immediate Release
  • Route Of Administration
    • Oral
    • Topical
  • Distribution Channel
    • Hospital Pharmacy
      • Private
      • Public
    • Online Pharmacy
      • Branded Portal
      • Third-Party Marketplace
    • Retail Pharmacy
      • Chain
      • Independent
  • End User
    • Clinics
      • Dermatology
      • Urology
    • Home Care
      • Caregiver-Administered
      • Self-Administered
    • Hospitals
      • General
      • Specialty
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Bio-Rad Laboratories, Inc.
  • Fulgent Genetics, Inc.
  • Invitae Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. 5-Alpha Reductase Deficiency Market, by Treatment Type
8.1. Introduction
8.2. Dutasteride
8.3. Finasteride
9. 5-Alpha Reductase Deficiency Market, by Formulation
9.1. Introduction
9.2. Capsule
9.2.1. Extended Release
9.2.2. Immediate Release
9.3. Solution
9.3.1. Concentrated
9.3.2. Standard
9.4. Tablet
9.4.1. Extended Release
9.4.2. Immediate Release
10. 5-Alpha Reductase Deficiency Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.3. Topical
11. 5-Alpha Reductase Deficiency Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Private
11.2.2. Public
11.3. Online Pharmacy
11.3.1. Branded Portal
11.3.2. Third-Party Marketplace
11.4. Retail Pharmacy
11.4.1. Chain
11.4.2. Independent
12. 5-Alpha Reductase Deficiency Market, by End User
12.1. Introduction
12.2. Clinics
12.2.1. Dermatology
12.2.2. Urology
12.3. Home Care
12.3.1. Caregiver-Administered
12.3.2. Self-Administered
12.4. Hospitals
12.4.1. General
12.4.2. Specialty
13. 5-Alpha Reductase Deficiency Market, by Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Americas 5-Alpha Reductase Deficiency Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa 5-Alpha Reductase Deficiency Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific 5-Alpha Reductase Deficiency Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Thermo Fisher Scientific Inc.
17.3.2. F. Hoffmann-La Roche AG
17.3.3. Illumina, Inc.
17.3.4. Danaher Corporation
17.3.5. Agilent Technologies, Inc.
17.3.6. QIAGEN N.V.
17.3.7. PerkinElmer, Inc.
17.3.8. Bio-Rad Laboratories, Inc.
17.3.9. Fulgent Genetics, Inc.
17.3.10. Invitae Corporation
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. 5-ALPHA REDUCTASE DEFICIENCY MARKET MULTI-CURRENCY
FIGURE 2. 5-ALPHA REDUCTASE DEFICIENCY MARKET MULTI-LANGUAGE
FIGURE 3. 5-ALPHA REDUCTASE DEFICIENCY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. 5-ALPHA REDUCTASE DEFICIENCY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. 5-ALPHA REDUCTASE DEFICIENCY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. 5-ALPHA REDUCTASE DEFICIENCY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CONCENTRATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STANDARD, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY BRANDED PORTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY THIRD-PARTY MARKETPLACE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CHAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY UROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAREGIVER-ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SELF-ADMINISTERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GENERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 87. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 89. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 90. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 91. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 92. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 95. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 96. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 97. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 99. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 100. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 101. CANADA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 106. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 107. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 110. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 111. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 112. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 115. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 180. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 181. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 182. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 183. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 186. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 187. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 188. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 190. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 191. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. GERMANY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 195. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 196. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 197. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 198. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 201. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 202. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 203. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 205. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 206. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. FRANCE 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 225. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 226. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 227. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 228. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 231. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 232. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 233. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 235. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 236. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 237. ITALY 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 240. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 241. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 242. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 243. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 246. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 247. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 248. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 251. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. SPAIN 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. SAUDI ARABIA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 288. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 292. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 296. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 298. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 299. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 300. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 301. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY SOLUTION, 2018-2030 (USD MILLION)
TABLE 302. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 303. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 306. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 307. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 308. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 310. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 311. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 312. DENMARK 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. NETHERLANDS 5-ALPHA REDUCTASE DEFICIENCY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 314. NETHER

Companies Mentioned

The companies profiled in this 5-Alpha Reductase Deficiency market report include:
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Bio-Rad Laboratories, Inc.
  • Fulgent Genetics, Inc.
  • Invitae Corporation

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.41 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.26 Billion
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

5-Alpha Reductase Deficiency Market Report 2025 - Product Image

5-Alpha Reductase Deficiency Market Report 2025

  • Report
  • 200 Pages
  • Global
From
BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030 - Product Image

BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030

  • Report
  • 329 Pages
  • Global
From
5-Alpha Reductase Inhibitor - Pipeline Insight, 2025 - Product Image

5-Alpha Reductase Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Aldose Reductase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Aldose Reductase Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Ribonucleotide Reductase Inhibitors - Pipeline Insight, 2025 - Product Image

Ribonucleotide Reductase Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the 5 Alpha Reductase Deficiency Drugs Market

Alpha Reductase Deficiency Drugs are a class of drugs used to treat a rare genetic disorder known as 5-alpha reductase deficiency. This disorder is characterized by the body's inability to produce the enzyme 5-alpha reductase, which is responsible for converting testosterone into dihydrotestosterone (DHT). Without this enzyme, the body is unable to produce DHT, which is essential for normal sexual and reproductive development. As a result, individuals with 5-alpha reductase deficiency may experience a range of symptoms, including incomplete male genitalia, infertility, and an inability to produce sperm. Alpha Reductase Deficiency Drugs are used to treat the symptoms of 5-alpha reductase deficiency by providing the body with the necessary enzyme. These drugs are typically administered orally or through injections, and may be used in combination with other treatments such as hormone replacement therapy. The Alpha Reductase Deficiency Drugs market is an important part of the Sexual and Reproductive Health Drugs market, as it provides a treatment option for individuals with 5-alpha reductase deficiency. This market is expected to grow in the coming years, as more individuals are diagnosed with the disorder and the need for effective treatments increases. Some companies in the Alpha Reductase Deficiency Drugs market include Merck, Pfizer, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.